Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Title:

Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a Phase 1 study in advanced solid tumors

Presenter:

Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center

Abstract Number:

CT019

Session:

New Frontiers in Precision Oncology

Date/Time:

April 27; 5:00 p.m. – 5:15 p.m. CST

Title:

Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitor

Presenter:

Anne Edwards, Ph.D.

Abstract Number:

ND06

Session:

New Drugs on the Horizon: Part 2

Date/Time:

April 27; 3:25 p.m. – 3:40 p.m. CST

Title:

Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)

Presenter:

Jia Luo, M.D., Dana-Farber Cancer Institute

Abstract Number:

LB218

Session:

Late-Breaking Research: Clinical Research 1

Date/Time:

April 28; 2:00 p.m. – 5:00 p.m. CST

Title:

Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies

Presenter:

Mallika Singh, Ph.D.

Abstract Number:

LB281

Session:

Late-Breaking Research: Experimental and Molecular Therapeutics 3

Date/Time:

April 29; 9:00 a.m. – 12:00 p.m. CST

Title:

Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapy

Presenter:

Mariela Moreno Ayala, Ph.D.

Abstract Number:

6046

Session:

Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity

Date/Time:

April 29; 2:00 p.m. – 5:00 p.m. CST

Title:

Distinct regulation of Cyclin D mediates heterogenous response to RAS inhibition in colorectal cancer models

Presenter:

Philip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

Abstract Number:

LB293

Session:

Late-Breaking Research: Experimental and Molecular Therapeutics 3

Date/Time:

April 29; 9:00 a.m. – 12:00 p.m. CST

Title:

Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRAS G12C amplification or NRAS G13R mutation

Presenter:

Hitendra Singh Solanki, Ph.D., Moffitt Cancer Center

Abstract Number:

5512

Session:

Drug Resistance in Molecular Targeted Therapies 3

Date/Time:

April 29; 2:00 p.m. – 5:00 p.m. CST

Title:

A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDAC

Presenter:

Caroline Broderick, Ph.D., Memorial Sloan Kettering Cancer Center

Abstract Number:

5336

Session:

CDK Inhibitors

Date/Time:

April 29; 2:00 p.m. – 5:00 p.m. CST

Title:

Preclinical evaluation of RMC-7977, a multi-selective RAS(ON) inhibitor, as a therapeutic strategy for KRAS-mutant cholangiocarcinoma

Presenter:

Jingjing Jiang, Ph.D.

Abstract Number:

5691

Session:

Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2

Date/Time:

April 29; 2:00 p.m. – 5:00 p.m. CST

Title:

Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer

Presenter:

Joshua H. Choe, Dana-Farber Cancer Institute

Abstract Number:

5507

Session:

Drug Resistance in Molecular Targeted Therapies 3

Date/Time:

April 29; 2:00 p.m. – 5:00 p.m. CST

Title:

T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC

Presenter:

Margo I. Orlen, Penn Medicine

Abstract Number:

6405

Session:

Checkpoints and Modulators of Tumor Microenvironment

Date/Time:

April 29; 3:25 p.m. – 3:40 p.m. CST